Aclarion (NASDAQ: ACON, ACONW) has announced the establishment of a second agreement with Weill Cornell Medicine to expand the use of Nociscan in a study titled “Bone Marrow Aspirate Concentrate Injection with MRI’s – a Prospective Randomized Controlled Trial.”
According to Aclarion, the agreement brings its Nociscan platform to Weill Cornell Medicine and Och Spine at New York-Presbyterian/Weill Cornell Medical Center through a trial led by renowned neurosurgeon, Roger Härtl, MD, the founder and director of the Weill Cornell Medicine Center for Comprehensive Spine Care and co-director of Och Spine at New York-Presbyterian.
In a statement, Dr. Härtl, commented, “Our scientific interest focuses on clinical and basic science research surrounding innovative and less invasive surgical and biological treatment strategies for degenerative diseases of the spine. This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging.”
Ryan Bond, chief strategy officer of Aclarion, added, “We are pleased to engage in this trial with Dr. Härtl and his team at Weill Cornell. Not only are Dr. Härtl and his colleagues renowned for their clinical excellence, their commitment to pioneering research is evident through this prospective randomized trial evaluating disc degeneration and the potential effects of bone marrow aspirate concentrate. Progressive trials such as this one are a clear example for how healthcare advances—investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan.”
